Brief: Groundbreaking EV-302 Trial Significantly Extends Overall Survival And Progression-Free Survival In Patients Treated With Padcev And Keytruda In First-Line Advanced Bladder Cancer
22/10/2023 17:04
Oct 22 (Reuters) - Seagen Inc SGEN.O :
* GROUNDBREAKING EV-302 TRIAL SIGNIFICANTLY EXTENDS OVERALL
SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH
PADCEV® (ENFORTUMAB VEDOTIN-EJFV) AND KEYTRUDA® (PEMBROLIZUMAB)
IN FIRST-LINE ADVANCED BLADDER CANCER
* RISK OF DEATH WAS REDUCED BY 53% IN PATIENTS TREATED WITH
ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB COMPARED TO CHEMOTHERAPY
* ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB IMPROVED MEDIAN
OVERALL
SURVIVAL BY MORE THAN 15 MONTHS VERSUS. CHEMOTHERAPY
* RESULTS WILL FORM BASIS OF GLOBAL REGULATORY SUBMISSIONS
Source text for Eikon: ID:nBw3bfC1Ga
Further company coverage: SGEN.O
((Reuters.Briefs@thomsonreuters.com;))